被撤回的出版物: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial (Publication with Expression of Concern. See vol. 8, 2022) (Retracted article. See vol. 9, 2022)

Article Respiratory System

Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial

Patricia R. M. Rocco et al.

Summary: In patients with mild COVID-19, there was no difference in symptom resolution between nitazoxanide and placebo groups after 5 days of treatment, but early nitazoxanide therapy significantly reduced viral load.

EUROPEAN RESPIRATORY JOURNAL (2021)

Add to Collection

Letter Dermatology

5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia

J. McCoy et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2

Yuanyuan Qiao et al.

Summary: Research has shown that androgens regulate the expression of ACE2, TMPRSS2, and AR in lung epithelial cells, affecting the risk of COVID-19 infection in males over 70 years old. The use of AR or BET antagonists can inhibit SARS-CoV-2 infection, providing support for further investigation into transcriptional inhibition for the treatment or prevention of COVID-19.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection

Article Microbiology

Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2

Tianling Ou et al.

Summary: Chloroquine and hydroxychloroquine have been shown to inhibit viral infection by targeting different pathways through which the SARS-CoV-2 spike protein is activated. SARS-CoV-2 relies more on the TMPRSS2 pathway for entry, while the presence of a furin-cleavage site in its spike protein further complicates the treatment with hydroxychloroquine alone. Combining hydroxychloroquine with a TMPRSS2 inhibitor may provide a more effective strategy to block SARS-CoV-2 infection.

PLOS PATHOGENS (2021)

Add to Collection

Article Virology

Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19

Hatem Elalfy et al.

Summary: This study compared the rate and time of viral clearance in patients receiving different treatments and found that patients in the combined antiviral group had a higher clearance rate.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide

Fei Li et al.

Summary: Enzalutamide effectively inhibited SARS-CoV-2 infection in human prostate cells, however, such antiviral efficacy was lacking in human lung cells and organoids.

NATURE COMMUNICATIONS (2021)

Add to Collection

Letter Dermatology

Response to Reply to effectiveness of dutasteride in a large series of patients with FFA in real clinical practice''

Cristina Pindado-Ortega et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

Flavio A. Cadegiani et al.

Summary: Proxalutamide significantly accelerated viral clearance on Day 7 in mild to moderate COVID-19 patients compared to placebo. Additionally, the time to clinical remission was significantly reduced in patients treated with Proxalutamide compared to placebo.

CUREUS JOURNAL OF MEDICAL SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical)

Flavio A. Cadegiani et al.

Summary: This study suggests that treatment with dutasteride in males with mild COVID-19 symptoms undergoing early therapy with nitazoxanide and azithromycin can significantly reduce viral shedding and inflammatory markers compared to those treated with a placebo.

CUREUS JOURNAL OF MEDICAL SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Potential risk for developing severe COVID-19 disease among anabolic steroid users

Flavio Cadegiani et al.

Summary: A 28-year-old man developed severe COVID-19 symptoms after taking the anabolic steroid oxandrolone for bodybuilding purposes. However, a marked improvement in symptoms and disease severity was observed after receiving a single dose of the novel antiandrogen proxalutamide, which is part of an experimental treatment for hyperandrogenic men with COVID-19. This case potentially links anabolic steroid use to COVID-19 disease severity.

BMJ CASE REPORTS (2021)

Add to Collection

Article Oncology